1801 Stock Overview
Innovent Biologics, Inc. operates as a biopharmaceutical company in China.
Price History & Performance
|Historical stock prices|
|Current Share Price||HK$71.20|
|52 Week High||HK$107.10|
|52 Week Low||HK$50.20|
|1 Month Change||2.01%|
|3 Month Change||13.56%|
|1 Year Change||39.47%|
|3 Year Change||197.91%|
|5 Year Change||n/a|
|Change since IPO||329.43%|
Recent News & Updates
Despite Lacking Profits Innovent Biologics (HKG:1801) Seems To Be On Top Of Its Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
|1801||HK Biotechs||HK Market|
Return vs Industry: 1801 exceeded the Hong Kong Biotechs industry which returned 24.1% over the past year.
Return vs Market: 1801 exceeded the Hong Kong Market which returned -6.3% over the past year.
|1801 Average Weekly Movement||7.0%|
|Biotechs Industry Average Movement||7.9%|
|Market Average Movement||6.8%|
|10% most volatile stocks in HK Market||13.3%|
|10% least volatile stocks in HK Market||3.3%|
Stable Share Price: 1801 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: 1801's weekly volatility (7%) has been stable over the past year.
About the Company
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin’s lymphoma, and esophageal carcinoma.
Innovent Biologics Fundamentals Summary
|1801 fundamental statistics|
Is 1801 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|1801 income statement (TTM)|
|Cost of Revenue||CN¥1.03b|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.07|
|Net Profit Margin||-32.61%|
How did 1801 perform over the long term?See historical performance and comparison
Is Innovent Biologics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 1801 (HK$71.2) is trading below our estimate of fair value (HK$116.29)
Significantly Below Fair Value: 1801 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 1801 is unprofitable, so we can't compare its PE Ratio to the Hong Kong Biotechs industry average.
PE vs Market: 1801 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 1801's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 1801 is overvalued based on its PB Ratio (7.2x) compared to the HK Biotechs industry average (4.4x).
How is Innovent Biologics forecast to perform in the next 1 to 3 years based on estimates from 23 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1801 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).
Earnings vs Market: 1801 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 1801's is expected to become profitable in the next 3 years.
Revenue vs Market: 1801's revenue (29.4% per year) is forecast to grow faster than the Hong Kong market (12.5% per year).
High Growth Revenue: 1801's revenue (29.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 1801's Return on Equity is forecast to be low in 3 years time (14.6%).
How has Innovent Biologics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 1801 is currently unprofitable.
Growing Profit Margin: 1801 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 1801 is unprofitable, and losses have increased over the past 5 years at a rate of 1.1% per year.
Accelerating Growth: Unable to compare 1801's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1801 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (49.4%).
Return on Equity
High ROE: 1801 has a negative Return on Equity (-13.15%), as it is currently unprofitable.
How is Innovent Biologics's financial position?
Financial Position Analysis
Short Term Liabilities: 1801's short term assets (CN¥13.4B) exceed its short term liabilities (CN¥2.2B).
Long Term Liabilities: 1801's short term assets (CN¥13.4B) exceed its long term liabilities (CN¥2.3B).
Debt to Equity History and Analysis
Debt Level: 1801 has more cash than its total debt.
Reducing Debt: Insufficient data to determine if 1801's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 1801 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 1801 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Innovent Biologics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 1801's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 1801's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 1801's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 1801's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 1801's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Michael Yu (57 yo)
Dr. De-Chao Yu, also known as Michael , Ph.D. co-founded Innovent Biologics, Inc. in August 2011 and has been its Chairman and Chief Executive Officer since 2011. He served as its President at Innovent Bio...
Experienced Management: 1801's management team is considered experienced (2.3 years average tenure).
Experienced Board: 1801's board of directors are considered experienced (3.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.2%.
Innovent Biologics, Inc.'s employee growth, exchange listings and data sources
- Name: Innovent Biologics, Inc.
- Ticker: 1801
- Exchange: SEHK
- Founded: 2011
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$103.931b
- Shares outstanding: 1.46b
- Website: https://www.innoventbio.com
Number of Employees
- Innovent Biologics, Inc.
- 168 Dongping Street
- Suzhou Industrial Park
- Jiangsu Province
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/11/29 15:57|
|End of Day Share Price||2021/11/29 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.